Sera Prognostics (NASDAQ:SERA) Trading Down 3.4% – Time to Sell?

Sera Prognostics, Inc. (NASDAQ:SERA) shares were down 3.4% during trading on Wednesday . The company traded as low as $1.97 and last traded at $2.01. Approximately 15,379 shares changed hands during trading, a decline of 43% from the average session volume of 26,750 shares. The stock had previously closed at $2.08.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SERA shares. Craig Hallum initiated coverage on Sera Prognostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target on the stock. Weiss Ratings downgraded Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Sera Prognostics has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Sera Prognostics Trading Down 3.4%

The company’s 50 day moving average is $2.03 and its 200 day moving average is $2.04. The company has a market cap of $79.29 million, a PE ratio of -3.00 and a beta of 0.98.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. Analysts expect that Sera Prognostics, Inc. will post -0.62 EPS for the current year.

Insider Activity

In related news, CEO Zhenya Lindgardt sold 20,755 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $2.08, for a total value of $43,170.40. Following the transaction, the chief executive officer owned 871,999 shares of the company’s stock, valued at $1,813,757.92. This represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 27,755 shares of company stock valued at $57,840 in the last ninety days. 11.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently made changes to their positions in SERA. Arkadios Wealth Advisors bought a new stake in shares of Sera Prognostics in the first quarter valued at about $25,000. Lido Advisors LLC bought a new position in Sera Prognostics during the 3rd quarter worth about $68,000. Cetera Investment Advisers bought a new position in Sera Prognostics during the 4th quarter worth about $74,000. Qube Research & Technologies Ltd purchased a new position in Sera Prognostics during the 2nd quarter valued at about $92,000. Finally, Two Sigma Investments LP purchased a new position in Sera Prognostics during the 3rd quarter valued at about $97,000. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.